Invesco recruits Stanton as MD and private equity head

Invesco Ltd has named Carl Stanton as managing director and head of private equity. Previously, he was a managing partner at Wellspring Capital Management.


ATLANTA, Feb. 21, 2018 /PRNewswire/ — Invesco Ltd. (NYSE: IVZ) announced today that it is expanding its Invesco Private Capital business by naming Carl Stanton as a Managing Partner and Head of Private Equity. In this newly created role, Stanton will broaden the scope of the firm’s existing private equity focus to include opportunistic buyouts and special situations. As part of the expansion the domestic activities of the firm’s WL Ross & Co unit have been rolled into Stanton’s group.

Stanton is an industry veteran with over 20 years of experience leading private equity investments and managing private equity teams. Prior to joining Invesco Private Capital, he was a managing partner at Wellspring Capital Management, a private equity firm focused on leverage buyout investments in middle-market companies across a broad range of industries.

“We are excited about the contributions that Carl can make to offer a broader array of financial solutions for our partners and investors,” said Greg Stoeckle who Co-Heads Invesco Private Capital along with Stephen Toy.
Stanton said, “I’m excited to be working amongst a world-class team at Invesco, and I’m looking forward to helping us expand our Private Equity platform.”

The move further defines the capabilities of Invesco Private Capital into four closely connected areas: Private Equity, Distressed Credit, WL Ross & Co. Asia and Venture Capital. Stoeckle added, “The alignment of these capabilities and the ability to share ideas across our private capital business along with access to the broader resources of Invesco create a uniquely strong platform that we can further build upon with the addition of Carl to our leadership team.”

About Invesco
Invesco is an independent investment management firm dedicated to delivering an investment experience that helps people get more out of life. NYSE: IVZ;